Withaferin A is additionally able to inhibit NF-kB activation secondary to inhibiting the degradation of IκBα (an inhibitor whose degradation is required to release active NF-kB), that is by blocking IKKβ (acts to degrade IκBα through phosphorylation) secondary on the MEK1/ERK pathway with an IC50 of 250nM reaching approximately 95%